Literature DB >> 21807457

The antimitogenic effect of the cannabinoid receptor agonist WIN55212-2 on human melanoma cells is mediated by the membrane lipid raft.

Mariagrazia Rita Scuderi1, Giuseppina Cantarella, Mimmo Scollo, Laurence Lempereur, Marco Palumbo, Gloria Saccani-Jotti, Renato Bernardini.   

Abstract

Here are reported the antiproliferative effects of the cannabinoid agonist WIN upon human melanoma cells expressing mRNA and protein for both CB1 and CB2 receptors. While WIN exerted antimitogenic effects, selective CB1 or CB2 agonists were unable to reproduce such effects and selective CB1 and CB2 antagonists did not inhibit WIN-induced cell death. Cells treated with WIN, preincubated with the lipid raft disruptor methylcyclodestrin, were rescued from death. WIN induced activation of caspases and phosphorylation of ERK that were attenuated in cultures treated with methylcyclodestrin. Membrane lipid raft complex-mediated antimitogenic effect of WIN in melanoma could represents a potential targets for a melanoma treatment.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21807457     DOI: 10.1016/j.canlet.2011.07.008

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  11 in total

1.  Endocannabinoids stimulate human melanogenesis via type-1 cannabinoid receptor.

Authors:  Mariangela Pucci; Nicoletta Pasquariello; Natalia Battista; Monia Di Tommaso; Cinzia Rapino; Filomena Fezza; Michela Zuccolo; Roland Jourdain; Alessandro Finazzi Agrò; Lionel Breton; Mauro Maccarrone
Journal:  J Biol Chem       Date:  2012-03-19       Impact factor: 5.157

2.  Combined antiproliferative effects of the aminoalkylindole WIN55,212-2 and radiation in breast cancer cells.

Authors:  Sean M Emery; Moureq R Alotaibi; Qing Tao; Dana E Selley; Aron H Lichtman; David A Gewirtz
Journal:  J Pharmacol Exp Ther       Date:  2013-11-20       Impact factor: 4.030

3.  The Synthetic Cannabinoid WIN55,212-2 Can Disrupt the Golgi Apparatus Independent of Cannabinoid Receptor-1.

Authors:  Joshua Lott; Emily M Jutkiewicz; Manojkumar A Puthenveedu
Journal:  Mol Pharmacol       Date:  2022-03-02       Impact factor: 4.054

Review 4.  Receptor-dependent and receptor-independent endocannabinoid signaling: a therapeutic target for regulation of cancer growth.

Authors:  Rukiyah Van Dross; Eman Soliman; Shalini Jha; Travious Johnson; Somnath Mukhopadhyay
Journal:  Life Sci       Date:  2012-10-12       Impact factor: 5.037

Review 5.  Cannabinoid Signaling in the Skin: Therapeutic Potential of the "C(ut)annabinoid" System.

Authors:  Kinga Fanni Tóth; Dorottya Ádám; Tamás Bíró; Attila Oláh
Journal:  Molecules       Date:  2019-03-06       Impact factor: 4.927

6.  Chronic Administration of Cannabinoid Receptor 2 Agonist (JWH-133) Increases Ectopic Ovarian Tumor Growth and Endocannabinoids (Anandamide and 2-Arachidonoyl Glycerol) Levels in Immunocompromised SCID Female Mice.

Authors:  Henry L Blanton; Melissa C McHann; Haley De Selle; Canice Lei Dancel; Jose-Luis Redondo; Deborah Molehin; Nadezhda A German; Scott Trasti; Kevin Pruitt; Isabel Castro-Piedras; Josée Guindon
Journal:  Front Pharmacol       Date:  2022-02-15       Impact factor: 5.810

Review 7.  Neuroendocrine Factors in Melanoma Pathogenesis.

Authors:  Cristian Scheau; Carmen Draghici; Mihaela Adriana Ilie; Mihai Lupu; Iulia Solomon; Mircea Tampa; Simona Roxana Georgescu; Ana Caruntu; Carolina Constantin; Monica Neagu; Constantin Caruntu
Journal:  Cancers (Basel)       Date:  2021-05-10       Impact factor: 6.639

8.  A chemoinformatics approach to the discovery of lead-like molecules from marine and microbial sources en route to antitumor and antibiotic drugs.

Authors:  Florbela Pereira; Diogo A R S Latino; Susana P Gaudêncio
Journal:  Mar Drugs       Date:  2014-01-27       Impact factor: 5.118

Review 9.  Cannabinoids Modulate Neuronal Activity and Cancer by CB1 and CB2 Receptor-Independent Mechanisms.

Authors:  Ken Soderstrom; Eman Soliman; Rukiyah Van Dross
Journal:  Front Pharmacol       Date:  2017-10-10       Impact factor: 5.810

Review 10.  Cannabinoids and their derivatives in struggle against melanoma.

Authors:  Paweł Marzęda; Małgorzata Drozd; Paula Wróblewska-Łuczka; Jarogniew J Łuszczki
Journal:  Pharmacol Rep       Date:  2021-07-15       Impact factor: 3.024

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.